HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictors of infection after pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension.

AbstractOBJECTIVE:
Pulmonary endarterectomy (PEA) is an effective and potentially curative treatment for chronic thrombo-embolic pulmonary hypertension (CTEPH). The postoperative course after PEA is accompanied by a number of complications, which contribute to the high rate of early postoperative mortality. Markers allowing the early detection of infectious complication during the postoperative period may be of major clinical importance. The aim of the prospective study was to analyse a predictive value of five inflammatory markers to recognise inflammatory complications accompanying PEA before the first clinical signs of infection.
METHODS:
Eighty-two patients with CTEPH, who underwent PEA using cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA), were included into the study. Procalcitonin (PCT), tumour necrosis factor-α, interleukin (IL)-6, IL-8 and C-reactive protein arterial concentrations were measured before sternotomy and repeatedly up to 72h after the end of surgery. Haemodynamic parameters, infectious and non-infectious complications were recorded.
RESULTS:
Postoperative course was uncomplicated in 59/82 patients (group 1). Fourteen out of 82 patients (group 2) developed an infection in the first 3 days after surgery (bronchopneumonia, n = 9; bacterial sepsis, n = 5). Nine out of 82 patients (group 3) developed non-infectious complications in the same period. PCT and IL-6 were the only significant independent predictors of infection in days 1-3 after PEA. The area under receiver operating characteristic (ROC) curve calculated for PCT to predict postoperative infection was 0.83 (95% confidence interval (CI): 0.74-0.92) compared with 0.74 (95% CI: 0.68-0.81) for IL-6. With the cut-off 2.3 ng ml(-1), the test characteristics of PCT were as follows: sensitivity, 86%; specificity, 83%; negative predictive value, 92%; and positive predictive value, 84%.
CONCLUSIONS:
The increase in PCT and IL-6 may allow patients at increased risk of infection after PEA to be identified, allowing earlier institution of antibiotic treatment. These changes that occur before infection can be detected clinically. This finding may make the daily monitoring of PCT post-PEA useful.
AuthorsPavel Maruna, Jan Kunstyr, Katerina M Plocova, Frantisek Mlejnsky, Jaroslav Hubacek, Andrew A Klein, Jaroslav Lindner
JournalEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (Eur J Cardiothorac Surg) Vol. 39 Issue 2 Pg. 195-200 (Feb 2011) ISSN: 1873-734X [Electronic] Germany
PMID20615721 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers
  • CALCA protein, human
  • Inflammation Mediators
  • Interleukin-6
  • Protein Precursors
  • Calcitonin
  • C-Reactive Protein
  • Calcitonin Gene-Related Peptide
Topics
  • Aged
  • Bacterial Infections (blood, diagnosis, etiology)
  • Biomarkers (blood)
  • C-Reactive Protein (metabolism)
  • Calcitonin (blood)
  • Calcitonin Gene-Related Peptide
  • Cardiopulmonary Bypass
  • Early Diagnosis
  • Endarterectomy (methods)
  • Epidemiologic Methods
  • Female
  • Humans
  • Hypertension, Pulmonary (etiology, surgery)
  • Inflammation Mediators (blood)
  • Interleukin-6 (blood)
  • Male
  • Middle Aged
  • Postoperative Care (methods)
  • Postoperative Complications (blood, diagnosis)
  • Protein Precursors (blood)
  • Pulmonary Artery (surgery)
  • Pulmonary Embolism (complications, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: